Cover Image


Neurology Markets for Transdermal Patches

出版商 Greystone Research Associates 商品編碼 566319
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
神經疾病用經皮吸收貼片市場 Neurology Markets for Transdermal Patches
出版日期: 2017年10月16日 內容資訊: 英文




  • CNS疾病治療的未滿足需求
  • CNS治療藥的經皮給藥的市場機會


  • 罹患率、死亡率的變化、趨勢
  • CNS治療藥的需求
  • 競爭環境
  • 阻礙成長要素


  • 貼片的設計與結構
  • 經皮吸收貼片的製造、包裝
  • 貼片製造生態系統
  • CNS貼片經濟學
  • 被動式 vs 主動式遞送系統


  • ADHD
  • 阿茲海默症
  • 失智症
  • 憂鬱症
  • 偏頭痛
  • 噁心
  • 帕金森氏症
  • 不寧腿症候群
  • 思覺失調症


  • FDA核准完畢經皮CNS處方藥
  • MAO抑制劑
  • 膽鹼促效劑
  • 多巴胺促效劑
  • 中樞神經刺激藥
  • 5-HT3受體拮抗劑
  • FDA未核准經皮CNS成藥
  • 產品分析、市場評估:美國以外的地區
  • 策略因素、品牌的課題
  • 開發階段的經皮CNS處方藥
  • AChE抑制劑
  • 膽鹼促效劑
  • 多巴胺促效劑
  • 5-HT3受體拮抗劑
  • 血清素促效劑
  • 其他


  • 市場因素
  • 法律規章、核准
  • 臨床試驗
  • 適應症處方指南、非標籤藥物處方
  • Rx-to-OTC交換器
  • 介面貼片的收益模式


Product Code: TCS912F

Unlike several other disease segments, progress toward curative medicine for neurological and related central nervous system disorders has remained elusive. The result is a therapeutic segment that relies heavily on control of symptoms and palliative care. These trends include the growing incidence of neurological disorders associated with longevity and aging, and significant increases in the number of children diagnosed with autism. Because diseases of the central nervous system often result in compromised cognitive and/or motor skills that can increase the level of involuntary non-compliance with therapeutic protocols, transdermal delivery of drugs targeting CNS disorders is generally viewed as a method that can increase patient safety and improve outcomes. In addition to the handful of FDA-approved transdermal CNS products, more than a dozen companies are currently pursuing a range of APIs in transdermal delivery systems that target neurological and CNS conditions. While none of these development-stage candidates is curative, the benefits they can offer in terms of patient ease-of-use, product safety and overall quality-of-care are expected to result in reduced morbidity and more effective symptom management for afflicted patients

Table of Contents

Neurology Markets for Transdermal Patches - Summary of Contents

Executive Summary

The Current CNS Drug Therapeutics Market

  • Unmet Needs in CNS Disease Treatment
  • The Opportunity for Transdermal Delivery of CNS Therapeutics

The CNS Therapeutics Market Opportunity

  • Changes and Trends in Incidence and Morbidity
  • The Demand Picture for CNS Therapeutics
  • Competitive Landscape
  • Factors Limiting Growth

Transdermal Drug Delivery to the CNS

  • Patch Designs and Construction
  • Transdermal Patch Manufacturing and Packaging
  • The Patch Manufacturing Ecosystem
  • CNS Patch Economics
  • Passive vs Active Delivery Systems

The Global Market for Transdermal CNS Therapeutics -Disease Segment Analysis

  • ADHD
  • Alzheimer's Disease
  • Dementia
  • Depression
  • Migraine
  • Nausea
  • Parkinson's Disease
  • Restless Leg Syndrome
  • Schizophrenia

Transdermal CNS Drug Product Analysis and Market Assessments

  • FDA Approved Transdermal CNS Prescription Products
  • MAO Inhibitors
  • Cholinergic Agents
  • Dopamine Agonists
  • CNS Stimulants
  • 5-HT3 Receptor Antagonists
  • Non-FDA Approved Commercial Transdermal CNS Products
  • Non-U.S. Regional Product Assessment & Market Impact
  • Strategic Factors and Branding Issues
  • Development-Stage Transdermal CNS Prescription Products
  • AChE Inhibitors
  • Cholinergic Agents
  • Dopamine Agonists
  • 5-HT3 Receptor Antagonists
  • Serotonin Agonists
  • Other Drug Classes

Transdermal CNS Therapeutics Market Data & Forecasts

  • Market Factors
  • Regulations and Approvals
  • Clinical Trials
  • Indications Prescribing Guidelines and Off-Label Prescribing
  • Rx-to-OTC Switching
  • Skin Patch Revenue Models

Market Participant Profiles

Back to Top